Home > Insider Trading > Filing (0001437749-21-003517)

Filing Details

Accession Number:: 0001437749-21-003517
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-02-19 20:01:55
Reporting Period:: 2021-02-08

Accepted Time:: 2021-02-19 20:01:55
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
834365	Biolife Solutions Inc	BLFS	Electromedical & Electrotherapeutic Apparatus (3845)	943076866

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1556355	J. Aby Mathew	C/O Biolife Solutions, Inc. 3303 Monte Villa Parkway, Suite 310 Bothell WA 98021	Exec Vp & Chief Scientific Off	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-02-08	4,891	$0.00	185,313	No	4	A	Direct
Common Stock	Acquisiton	2021-02-08	33,196	$0.00	218,509	No	4	M	Direct
Common Stock	Disposition	2021-02-17	4,640	$41.55	213,869	No	4	S	Direct
Common Stock	Disposition	2021-02-18	4,741	$40.67	209,128	No	4	S	Direct
Common Stock	Disposition	2021-02-19	4,728	$40.76	204,400	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Award	Acquisiton	2021-02-08	4,891	$0.00	4,891	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
4,891			No	4	A	Direct

Footnotes

The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2021 compensation.
The reporting person was granted restricted stock pursuant to the Plan on February 25, 2019. In accordance with the terms of the grant, the restricted stock vested as to 200% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2019 through December 31, 2020 as compared to the total shareholder return of 20 of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).
The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.
The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period.